Proceedings of the 13th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2026
Vol. 5 No. s1 (2026)
Anticoagulation challenges in patients with hematological malignancy-associated thrombosis and severe thrombocytopenia
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 16 April 2026
0
Views
0
Downloads
Authors
Patients with cancer are at increased risk of venous thromboembolism (VTE), with incidence rates of 5-20% depending on tumor type, stage, and treatment. The coexistence of cancer-associated thrombosis (CAT) and thrombocytopenia is a particularly challenging therapeutic dilemma, occurring in nearly half of patients with hematologic malignancies and in about one-fifth of patients with solid tumors who require anticoagulation. This review looks at the most recent research on how to manage anticoagulation in people with hematological malignancy-associated thrombosis and severe thrombocytopenia (a platelet count of less than 50×10⁹/L). Robust data are limited because pivotal trials systematically excluded patients with moderate-to-severe thrombocytopenia when establishing the standard of care for CAT treatment. The existing evidence largely comes from small retrospective studies and only three prospective observational studies, which predominantly enrolled patients with hematologic cancers. These studies demonstrate variability in clinical practice encompassing full-intensity anticoagulation with platelet transfusion support, reduced-dose regimens, and treatment interruption. Major bleeding rates ranged from 3% to 13%, while VTE recurrence occurred in 0% to 6% of cases across different management approaches. Current guidelines generally agree on the need for personalized treatment decisions guided by VTE severity, bleeding risk assessment, and platelet count trajectory. However, platelet counts alone demonstrate poor predictive value for bleeding events, and maintaining platelet counts above 50×10⁹/L through transfusion does not consistently prevent hemorrhagic complications. Optimal management requires tailored, multidisciplinary approaches. The forthcoming START trial will compare the efficacy of dose-adjusted anticoagulation versus transfusion-supported full-dose therapy, which could establish an evidence-based standard of care for this vulnerable population.
Downloads
Download data is not yet available.
Citations
1. Khorana AA, Mackman N, Falanga A, et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers 2022;8:11. DOI: https://doi.org/10.1038/s41572-022-00336-y
2. Abdulla A, Davis WM, Ratnaweera N, et al. A meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer. Thromb Haemost 2020;120:702‑13. DOI: https://doi.org/10.1055/s-0040-1708481
3. Shaw JL, Nielson CM, Park JK, et al.The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies. Eur J Haematol 2021;106:662‑72. DOI: https://doi.org/10.1111/ejh.13595
4. Kilpatrick K, Shaw JL, Jaramillo R, et al. Occurrence and management of thrombocytopenia in metastatic colorectal cancer patients receiving chemotherapy: secondary analysis of data from prospective clinical trials. Clin Colorectal Cancer 2021;20:170‑6. DOI: https://doi.org/10.1016/j.clcc.2020.10.004
5. Samuelson Bannow BR, Lee AYY, et al. Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review. Res Pract Thromb Haemost 2018;2:664‑9. DOI: https://doi.org/10.1002/rth2.12111
6. Samuelson Bannow BT, Lee A, Khorana AA, et al. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost 2018;16:1246‑9. DOI: https://doi.org/10.1111/jth.14015
7. Hsu C, Patell R, Zwicker JI. The prevalence of thrombocytopenia in patients with acute cancer-associated thrombosis. Blood Adv 2023;7:4721-7. DOI: https://doi.org/10.1182/bloodadvances.2022008644
8. Bindal P, Patell R, Chiasakul T, et al. A meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. J Thromb Haemost 2024;22:2071-80. DOI: https://doi.org/10.1016/j.jtha.2024.03.021
9. Lecumberri R, Ruiz-Artacho P, Trujillo-Santos J, et al. Management and outcomes of cancer patients with venous thromboembolism presenting with thrombocytopenia. Thromb Res 2020;195:139‑45.
10. Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146‑53. DOI: https://doi.org/10.1056/NEJMoa025313
11. Lee AYY, Kamphuisen PW, Meyer G, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015;314:677‑86. DOI: https://doi.org/10.1001/jama.2015.9243
12. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018;378:615‑24. DOI: https://doi.org/10.1056/NEJMoa1711948
13. Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018;36:2017‑23.
14. McBane RD, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost 2020;18:411‑21. DOI: https://doi.org/10.1111/jth.14662
15. Agnelli G, Becattini C, Meyer G, et al. Apixaban for the Treatment of venous thromboembolism associated with cancer. N Engl J Med 2020;382:1599‑607. DOI: https://doi.org/10.1056/NEJMoa1915103
16. Planquette B, Bertoletti L, Charles-Nelson A, et al. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest 2022;161:781‑90.
17. Ibrahim RB, Peres E, Dansey R, et al. Safety of low-dose low-molecular-weight-heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literature. Bone Marrow Transplant 2005;35:1071‑7. DOI: https://doi.org/10.1038/sj.bmt.1704952
18. Babilonia KM, Golightly LK, Gutman JA, et al. Antithrombotic therapy in patients with thrombocytopenic cancer: outcomes associated with reduced-dose, low-molecular-weight heparin during hospitalization. Clin Appl Thromb Hemost 2014;20:799‑806. DOI: https://doi.org/10.1177/1076029614543140
19. Kopolovic I, Lee AYY, Wu C. Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study. Ann Hematol 2015;94:329‑36. DOI: https://doi.org/10.1007/s00277-014-2198-6
20. Khanal N, Bociek RG, Chen B, et al. Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia. Am J Hematol 2016;91:E468‑72. DOI: https://doi.org/10.1002/ajh.24526
21. Campbell PM, Ippoliti C, Parmar S. Safety of anticoagulation in thrombocytopenic patients with hematologic malignancies: A case series. J Oncol Pharm Pract 2017;23:220‑5. DOI: https://doi.org/10.1177/1078155216631407
22. Li A, Davis C, Wu Q, et al. Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation. Blood Adv 2017;1:707‑14. DOI: https://doi.org/10.1182/bloodadvances.2017006130
23. Mantha S, Miao Y, Wills J, et al. Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study. J Thromb Thrombolysis 2017;43:514‑8. DOI: https://doi.org/10.1007/s11239-017-1478-0
24. Samuelson Bannow BT, Walter RB, Gernsheimer TB, Garcia DA. Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes. J Thromb Thrombolysis 2017;44:442‑7. DOI: https://doi.org/10.1007/s11239-017-1539-4
25. Houghton DE, Key NS, Zakai NA, et al. Analysis of anticoagulation strategies for venous thromboembolism during severe thrombocytopenia in patients with hematologic malignancies: a retrospective cohort. Leuk Lymphoma 2017;58:2573‑81. DOI: https://doi.org/10.1080/10428194.2017.1306644
26. Htun KT, Ma MJY, Lee AYY. Incidence and outcomes of catheter related thrombosis (CRT) in patients with acute leukemia using a platelet-adjusted low molecular weight heparin regimen. J Thromb Thrombolysis 2018;46:386‑92. DOI: https://doi.org/10.1007/s11239-018-1711-5
27. Lecumberri R, Ruiz-Artacho P, Trujillo-Santos J, et al. Management and outcomes of cancer patients with venous thromboembolism presenting with thrombocytopenia. Thromb Res 2020;195:139‑45. DOI: https://doi.org/10.1016/j.thromres.2020.07.021
28. Scamuffa MC, Morano SG, Serrao A, et al. PICC-related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count. J Thromb Thrombolysis 2020;49:426‑30. DOI: https://doi.org/10.1007/s11239-020-02040-8
29. Wilson NR, Khan M, Cox TM, et al. Bleeding outcomes in thrombocytopenic acute leukemic patients with venous thromboembolism. eJHaem 2020;1:448‑56. DOI: https://doi.org/10.1002/jha2.90
30. Lam J, Tavares E, Luk SO. Outcomes with enoxaparin dose reductions during thrombocytopenia in patients with hematopoietic stem cell transplantation (HSCT). J Oncol Pharm Pract 2021;27:1364‑70. DOI: https://doi.org/10.1177/1078155220957747
31. Martens KL, Amos CI, Hernandez CR, et al. Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation. Am J Hematol 2021;96:1137‑46.
32. Squizzato A, Galliazzo S, Rancan E, et al. Current management of cancer-associated venous thromboembolism in patients with thrombocytopenia: a retrospective cohort study. Intern Emerg Med 2022;17:83‑90. DOI: https://doi.org/10.1007/s11739-021-02771-3
33. Abbas U, MacKenzie R, Khan U, et al. Anticoagulant management of cancer-associated thrombosis and thrombocytopenia: a retrospective chart review. Res Pract Thromb Haemost 2025;9:102684. DOI: https://doi.org/10.1016/j.rpth.2025.102684
34. Carney BJ, Wang TF, Ren S, et al. Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study. Blood Adv 2021;55546‑53.
35. Booth S, Network TH, Desborough M, et al. Platelet transfusion and anticoagulation in hematological cancer‐associated thrombosis and thrombocytopenia: The CAVEaT multicenter prospective cohort. J Thromb Haemost 2022;20:1830‑8. DOI: https://doi.org/10.1111/jth.15748
36. Jalaber E, Orvain C, Papadopoulou V, et al. Management of thrombocytopenia and anticoagulant therapy in patients with hematological malignancy on chemotherapy: a binational prospective study (TAT study). J Thromb Thrombolysis 2025;58:646‑56. DOI: https://doi.org/10.1007/s11239-025-03085-3
37. Wang TF, Carrier M, Carney BJ, et al. Anticoagulation management and related outcomes in patients with cancer-associated thrombosis and thrombocytopenia: A systematic review and meta-analysis. Thromb Res 2023;227:8‑16. DOI: https://doi.org/10.1016/j.thromres.2023.05.012
38. Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2020;38:496‑520. DOI: https://doi.org/10.1200/JCO.19.01461
39. Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021;5:927‑74. DOI: https://doi.org/10.1182/bloodadvances.2021004734
40. Farge D, Frere C, Connors JM, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 2022;23:e334‑47.
41. Falanga A, Ay C, Nisio MD, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol 2023;34:452‑67. DOI: https://doi.org/10.1016/j.annonc.2022.12.014
42. Laporte S, Benhamou Y, Bertoletti L, et al. Management of cancer-associated thromboembolism in vulnerable population. Arch Cardiovasc Dis 2024;117:45‑59. DOI: https://doi.org/10.1016/j.acvd.2023.11.009
43. National Comprehensive Cancer Network [Internet]. NCCN guideline on cancer-associated venous thromboembolic disease. Version 3. 2025. Available from: https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf
44. Falanga A, Leader A, Ambaglio C, et al. EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer. Hemasphere 2022;6:e750. DOI: https://doi.org/10.1097/HS9.0000000000000750
45. Uhl L, Assmann SF, Hamza TH et al. Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial. Blood 2017;130:1247‑58. DOI: https://doi.org/10.1182/blood-2017-01-757930
46. Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 2012;380:1309‑16. DOI: https://doi.org/10.1016/S0140-6736(12)60689-8
47. Stanworth SJ, Estcourt LJ, Powter G, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med 2013;368:1771‑80. DOI: https://doi.org/10.1056/NEJMoa1212772
48. Estcourt LJ, Stanworth SJ, Harrison P, et al. Prospective observational cohort study of the association between thromboelastometry, coagulation and platelet parameters and bleeding in patients with haematological malignancies - The ATHENA study. Br J Haematol 2014;166:581‑91.
49. Webert K, Cook RJ, Sigouin CS, et al. The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica 2006;91:1530‑7.
50. Frere C, Font C, Esposito F, et al. Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis. Support Care Cancer 2022;30:2919‑31. DOI: https://doi.org/10.1007/s00520-021-06598-8
51. Khan F, Tritschler T, Marx CE, et al. Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis. Eur Heart J 2025:ehaf453. Online Ahead of Print. DOI: https://doi.org/10.1093/eurheartj/ehaf453
52. Stanworth SJ, Hudson CL, Estcourt LJ, et al. Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica 2015;100:740‑7. DOI: https://doi.org/10.3324/haematol.2014.118075
53. Elting LS, Rubenstein EB, Martin CG, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 2001;19:1137‑46. DOI: https://doi.org/10.1200/JCO.2001.19.4.1137
54. Martens KL, Amos CI, Hernandez CR, et al. Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation. Am J Hematol 2021;96:1137‑46. DOI: https://doi.org/10.1002/ajh.26268
55. Martens KL, da Costa WL, Amos CI, et al. HIGH-2-LOW risk model to predict venous thromboembolism in allogeneic transplant patients after platelet engraftment. Blood Adv 2021;5:167‑75. DOI: https://doi.org/10.1182/bloodadvances.2020003353
56. Klok FA, Hösel V, Clemens A, et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J 2016;48:1369‑76. DOI: https://doi.org/10.1183/13993003.00280-2016
57. Ruíz-Giménez N, Suárez C, González R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008;100:26‑31. DOI: https://doi.org/10.1160/TH08-03-0193
58. de Winter MA, Dorresteijn JAN, Ageno W, et al. Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score. Thromb Haemost 2022;122:818‑29. DOI: https://doi.org/10.1055/s-0041-1735251
59. Estcourt LJ, Stanworth SJ, Harrison P, et al. Prospective observational cohort study of the association between thromboelastometry, coagulation and platelet parameters and bleeding in patients with haematological malignancies- The ATHENA study. Br J Haematol 2014;166:581‑91. DOI: https://doi.org/10.1111/bjh.12928
60. Wang TF, Thomas M, Cervi A, et al. Strategies for anticoagulation in patients with thrombocytopenia and cancer-associated thrombosis (START): design and rationale of the START pilot randomized controlled trial. Res Pract Thromb Haemost 2025;9:10289. DOI: https://doi.org/10.1016/j.rpth.2025.102898
61. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017. Available from: https://dctd.cancer.gov/research/ctep-trials/for-sites/adverse-events/ctcae-v5-5x7.pdf
How to Cite
1.
Chalayer E, Poenou G, Frere C. Anticoagulation challenges in patients with hematological malignancy-associated thrombosis and severe thrombocytopenia. Bleeding Thromb Vasc Biol [Internet]. 2026 Apr. 16 [cited 2026 Apr. 17];5(s1). Available from: https://www.btvb.org/btvb/article/view/429
Copyright (c) 2026 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
